Note 11 - Equity (Tables)

9 Months Ended

Sep. 30, 2024

Stockholders' Equity Note [Abstract]

Summary of Stock-Based Award Activity

The following table summarizes the stock-based award activity under the Plan for the nine months ended September 30, 2024 and 2023.

	Restricted Stock Awards			Weighted-Average Grant Date Fair Value Per Restricted Stock Award
Outstanding as of December 31, 2023		775,369		$	0.99
Granted		1,519,154			0.40
Vested		(190,665	)		1.20
Outstanding as of September 30, 2024		2,103,858		$	0.54

	Restricted Stock Awards			Weighted-Average Grant Date Fair Value Per Restricted Stock Award
Outstanding as of December 31, 2022		159,439		$	2.24
Granted		419,618			0.78
Vested		(59,607	)		2.25
Forfeitures		(19,791	)		1.69
Outstanding as of September 30, 2023		499,659		$	1.04

Summary of Option Awards

In connection with the completion of the Initial Mergers, the Company assumed option awards previously issued to directors and officers of MedAmerica. Details of these options for the nine months ended September 30, 2023 are presented in the tables below:

	Number of Shares Underlying Options			Weighted Average Exercise Price Per Share			Weighted Average Fair Value at Grant Date		Weighted Average Remaining Contractual Life		Intrinsic Value
Balance at December 31, 2022		10,000		$	6.00		$	—		0.45	$	—
Options granted		—			—			—		—		—
Options exercised		—			—			—		—		—
Options expired		(10,000	)		(6.00	)		—		—		—
Balance at September 30, 2023		—		$	—		$	—		—	$	—